Congress Presentation Headlines
The theme of our 6th International Vaccine Science Congress to be held in our country is “The Key to One Health: Vaccines,” and your oral or poster presentations will be evaluated under the following presentation topics.
CONGRESS PRESENTATION TOPICS
1) Current approaches in vaccine technologies
Inactivated, attenuated, toxoid, recombinant protein, peptide, VLP, OMV, viral vector, DNA, mRNA, self-amplifying RNA, saRNA, saRNA vs. classical mRNA comparisons)
2) Antigen discovery & structural/multi-omics approaches
Target antigen/epitope discovery using proteomics (MS), single-cell omics, B-cell repertoire sequencing, and structural virology.
3) In silico antigen design & immunoinformatics
Multi-epitope vaccine designs, HLA coverage analyses, population-focused epitope selections; the role of AlphaFold and deep learning in design.
4) Vaccine development using artificial intelligence (AI) and machine learning
Antigen prioritization, adjuvant/format optimization, prediction of patient-subgroup responses; current successes of DL-based models.
5) Mucosal and intranasal vaccines; alternative routes of administration
oral, inhaler, microneedle, patch, etc.
6) Vaccines against infectious diseases
SARS-CoV-2 (next-gen, pan-coronavirus), Influenza (universal approaches), RSV, Hepatitis, Malaria, Tuberculosis, Pneumococcus, Meningococcus, etc.
7) Vaccines against non-communicable diseases
Cancer vaccines (neoantigen, personalized), allergy vaccines, vaccination research targeting neurological targets.
8) Veterinary vaccines
Animal health vaccines, vaccine strategies targeting zoonotic reservoirs, and human-animal-environment (One Health) applications. Vaccination in wildlife.
9) Vaccine strategies for neglected diseases
Regional priorities, financing models, and situation assessment (e.g., Chagas, Leishmania, Rift Valley, etc.).
10) Adjuvants: next-generation and mechanism studies
CpG/TLR agonists, alum surfaces, saponin-based adjuvants (such as Matrix-M), liposomal adjuvants, nanoparticle-based adjuvant development, LNP/formulation developments, and efforts to reduce cold chain requirements.
11) Vaccine immunology
Antibody/ADCC/ADCP, T-cell subsets, immune memory, mucosal IgA, immunosenescence, and immunoregulation.
12) Preclinical models and selection of animal models
Humanized mice, primates, zoonotic models, and model limitations in addition to traditional models.
13) Controlled human infection models (CHIM) and the ethical-legal framework
CHIM design criteria, risk mitigation, regulation, and application examples.
14) GMP manufacturing, modular/distributed manufacturing approaches
mRNA technology transfers and regional hubs; modular/portable manufacturing facilities, in-process control, and regulatory requirements.
15) Toxicity, safety assessments & Non-clinical safety
GLP toxicology, safety pharmacology, and immunopathology assessments.
16) Clinical research: project file preparation and phase studies
Phase 1–4 planning, ethical and regulatory application processes, accelerated approval pathways, and data requirements.
17) Real-world evidence (RWE), post-marketing safety surveillance, and pharmacovigilance
Big data, databases, post-vaccination efficacy, and safety signal detection.
18) Epidemiology & surveillance strategies
Surveillance infrastructure, genomic tracking, and variant monitoring.
19) Vaccination policies, economics, and financing
Health technology assessments, cost-effectiveness, supply chain sustainability, and financing models.
20) Vaccine hesitancy, communication strategies, and combating misinformation
Socio-psychological reasons, combating social media disinformation, risk communication methods.
21) Vaccination of specific risk groups
Pregnancy/maternal immunization, immunodeficiencies, elderly, pediatrics, safety data during pregnancy.
22) Vaccination programs, maternal immunization, and implementation operations
Program design, supply, distribution, cold chain, and field implementation optimization.
23) Regulation and ethics: global and regional updates
Emergency use authorizations, variant-based updates, clinical endpoint discussions.
24) One Health: Implementation in complex settings and global preparedness
Pandemic preparedness, zoonotic early warning systems, health system resilience.
25) Advanced production techniques: cell-free/synthetic biology, cell line optimization
Cell-free synthesis, synthetic RNA production optimization, rapid GMP-compliant production methods.
26) Personalized and therapeutic vaccines: Personalized cancer vaccines, neoantigen studies
Clinical applications, production challenges, and regulation.
27) Foundation/support programs, global collaborations, and technology transfer
WHO mRNA hub example, regional capacity building, and technology sharing
